Mary Ann Anderson

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text

Medicine, Cancer Biology, Oncology +14

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 751 citations

Medicine, Hematology, Pharmacokinetics +15

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

Constantine S. Tam, Mary Ann Anderson, Christiane Pott et al. · New England Journal of Medicine · 2018 · 429 citations

Medicine, Pharmacology, Pharmacotherapy +13

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jianan Gong et al. · Cancer Discovery · 2018 · 426 citations · Full text

Life Sciences, Genetics, Hematology +10

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

Mary Ann Anderson, Jing Deng, John F. Seymour et al. · Blood · 2016 · 329 citations · Full text

Life Sciences, Cell Biology, Oncology +13